Sunday 18 October 2026
Export SPRB’s income statement to Excel — free account
Spruce Biosciences, Inc.
SPRB Healthcare Biotechnology
Spruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023. In the quarter to June 2026, revenue fell 75.9%, EPS fell 90.9%, free cash flow fell 152.1% and total debt rose 427.2%, each against the same quarter a year earlier.
39.65
1.82
−4.39%
Follow SPRB
Spruce Biosciences, Inc. (SPRB) P/E ratio
Spruce Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NRXP NRx Pharmaceuticals, Inc. compare | n/m |
| ENGN enGene Therapeutics Inc compare | n/m |
| ARMP Armata Pharmaceuticals, Inc. compare | n/m |
| SPRB Spruce Biosciences, Inc. | n/m |
| OTLK Outlook Therapeutics, Inc. compare | n/m |
| ABOS Acumen Pharmaceuticals, Inc. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HUMA Humacyte, Inc. compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)